Abstract: The present invention provides a “living” radical polymerization method for a vinyl monomer by near-infrared photothermal conversion. The method comprises irradiating a reactor with near-infrared light of 750-850 nm, wherein the reactor has a first chamber and a second chamber that are isolated from each other, the first chamber contains an organic solution of a near-infrared light responsive croconaine dye, and the second chamber is provided with a closed reaction flask containing a reaction solution, the reaction solution comprises a vinyl monomer, two or more of an ATRP initiator, an ATRP ligand, an ATRP catalyst, an RAFT reagent, a thermal initiator, and an additive, and an organic solvent; and the near-infrared light responsive dye converts the near-infrared light into heat energy, by which the reactor is heated to 50-100° C. to polymerize the monomer in the reaction solution, to obtain polymers with controlled molecular weights and molecular weight distributions.

Abstract: The present invention provides a fluorine-containing liquid crystal polymer of Formula (1). The present invention also discloses a fluorine-containing liquid crystal elastomer, which comprises a copolymer of a fluorine-containing liquid crystal polymer of Formula (1) with a near-infrared dye of Formula (2). The fluorine-containing liquid crystal elastomer of the present invention shrinks due to the photothermal conversion effect of the material under the irradiation of near-infrared light, and thus is widely applicable to the field of actuators. The fluorine-containing liquid crystal polymer of the present invention introduces fluorine-containing segments into the cross-linked network of the liquid crystal polymer, to improve the mechanical performance of the material, and greatly extend the service time of light-controlled actuators.

Abstract: The invention provides antibodies that specifically bind to PD-L1 and fusion molecules comprising PD-L1 binding proteins constructed with an IL 15 receptor-binding domain, nucleic acid molecules encoding the same, and therapeutic compositions thereof. The agents inhibit PD-L1-mediated immunosuppression and enhance cell and cytokine mediated immunity for the treatment of neoplastic and infectious diseases.

Abstract: The present invention relates to an antibody binding to human IL-33 or an antigen-binding fragment thereof, which can bind to the human IL-33 with a high affinity and block the binding of ST2 to IL-33, can be used in the preparation of a drug for treating diseases with a high IL-33 expression (such as asthma, atopic/allergic dermatitis, chronic rhino sinusitis and chronic obstructive pulmonary diseases (COPD)), and has good clinical application prospects.

Abstract: The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.

Abstract: An antibody or an antigen-binding fragment thereof that binds to human CD38. The antibody or the antigen-binding fragment thereof can effectively bind to human CD38 and is applied to preparing a drug for treating diseases having strong CD38 expression (such as multiple myeloma), thereby having good prospects in clinical application.

Abstract: The present invention relates to the technical field of fusion proteins, and particularly to an SIRP?-Fc fusion protein. The fusion protein comprises an SIRP? D1 domain variant and an immunoglobulin Fc region. The fusion protein of the present invention has the potential to treat diseases associated with the SIRP?-CD47 signaling pathway.

Abstract: Provided are an anti-HER2/PD1 bispecific antibody, preparation method, and antitumor application. Specifically, a single-chain variable fragment scFv and an immunoglobulin antibody IgG are connected by means of a peptide linker to obtain a bispecific antibody; the bispecific antibody can simultaneously target the tumor cell surface molecule HER2 antigen and T lymphocyte surface molecule PD-1. The results of experimentation show that the bispecific antibody provided is capable of inhibiting the proliferation of HER2-positive tumor cells while also blockading the binding of PD-1/PD-L1, releasing the suppressive state of T cells and performing an antitumor function.

Abstract: Provided is an anti-PDL1×EGFR bispecific antibody. Experimental results show that the bispecific antibody can maintain relatively well the activity of anti-EGFR and anti-PD-L1 monoclonal antibodies; in addition, same can specifically bind to the two PD-L1 and EGFR targets at the same time, and more importantly, said bispecific antibody has obvious synergy at the cellular level.

Abstract: Disclosed are antibodies binding to human IL-4R, having identical variable regions and different constant regions, wherein the variable regions can specifically bind to human IL-4R, and the constant regions affect the activity of the whole antibody through an amino acid site mutation. The above-mentioned antibodies can be used to treat diseases related to IL-4R overexpression, such as atopic dermatitis, asthma, etc., and thus possesses good clinical application prospects.

Abstract: The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.

Abstract: Provided are an antibody that binds to human PD-L1, and a tetravalent bispecific antibody against PD-1 and PD-L1 constructed based on the antibody that binds to human PD-L1. The tetravalent bispecific antibody requires no Fc modification, has no mismatch problems, and the preparation method thereof is simple. The biological activities and physical and chemical properties of the tetravalent bispecific antibody are similar with or even better than those of the monoclonal antibodies.

Abstract: Provided is a method for preparing a recombinant human nerve growth factor, which can be used as a therapeutic drug.

Abstract: Provided are a structurally symmetrical tetravalent bispecific antibody based on a common light chain and a construction method therefor. The prepared tetravalent bispecific antibody has similar or even better biological activity and physical and chemical properties than monoclonal antibodies, and can be used for the treatment of various inflammatory diseases, cancer, and other diseases.

Abstract: Disclosed is a monoclonal antibody that binds to human IL-5. The monoclonal antibody that binds to human IL-5 has a good biological activity for inhibiting TF-1 cell proliferation induced by IL-5 and blocking the interaction between IL-5 and IL-5RA, has a different antigen epitope from the known anti-human IL-5 antibody, can be used for preparing drugs for treating diseases mediated by the over-expression of eosinophilic granulocytes (such as asthma), and has a good clinical application prospect.

Abstract: Provided are an antibody that binds to human PD-L1, and a tetravalent bispecific antibody against PD-1 and PD-L1 constructed based on the antibody that binds to human PD-L1. The tetravalent bispecific antibody requires no Fc modification, has no mismatch problems, and the preparation method thereof is simple. The biological activities and physical and chemical properties of the tetravalent bispecific antibody are similar with or even better than those of the monoclonal antibodies.

Abstract: Provided are a structurally symmetrical tetravalent bispecific antibody based on a common light chain and a construction method therefor. The prepared tetravalent bispecific antibody has similar or even better biological activity and physical and chemical properties than monoclonal antibodies, and can be used for the treatment of various inflammatory diseases, cancer, and other diseases.

Abstract: Provided are a structurally symmetrical tetravalent bispecific antibody based on a common light chain and a construction method therefor. The prepared tetravalent bispecific antibody has similar or even better biological activity and physical and chemical properties than monoclonal antibodies, and can be used for the treatment of various inflammatory diseases, cancer, and other diseases.

Abstract: Provided are a structurally symmetrical tetravalent bispecific antibody based on a common light chain and a construction method therefor. The prepared tetravalent bispecific antibody has similar or even better biological activity and physical and chemical properties than monoclonal antibodies, and can be used for the treatment of various inflammatory diseases, cancer, and other diseases.

Abstract: An anti-human PD-1 monoclonal antibody, and a preparation method therefor and an application thereof. The anti-human PD-1 monoclonal antibody has good bioactivity, can effectively bind with an extracellular region of a human PD-1 protein receptor, and can effectively seal PD-1 protein at protein level and cellular level and block the binding of the PD-1 protein with a ligand PD-L1, thereby effectively enhancing immunity. The monoclonal antibody can be applied independently or jointly with other antitumor drugs to tumor immunotherapy and the diagnosis and screening of patients with PD-L1 positive tumors; and the monoclonal antibody has a promising prospect in the preparation of drugs for treating tumors, resisting autoimmune diseases and the like.